Menu Search
Equities

Oculis Holding AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
OCS:ICX

Oculis Holding AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ISK)3,530.00
  • Today's Change60.00 / 1.73%
  • Shares traded83.31k
  • 1 Year change+16.12%
  • Beta0.1539
Data delayed at least 15 minutes, as of Feb 17 2026 16:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

  • Revenue in USD (TTM)0.00
  • Net income in USD-135.32m
  • Incorporated2022
  • Employees49.00
  • Location
    Oculis Holding AGBahnhofstrasse 20ZUG 6300SwitzerlandCHE
  • Phone+41 417113960
  • Websitehttps://oculis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.